Multisystem inflammatory syndrome in children in Singapore.
10.47102/annals-acadmedsg.202283
- Author:
Karen Donceras NADUA
1
;
Chia Yin CHONG
;
Kai Qian KAM
;
Yee Hui MOK
;
Jonathan Tze Liang CHOO
;
Joyce Ching Mei LAM
;
Jiahui LI
;
Natalie Woon Hui TAN
;
Chee Fu YUNG
;
Su Wan Bianca CHAN
;
Kai Liang TEH
;
Lena DAS
;
Thaschawee ARKACHAISRI
;
Koh Cheng THOON
Author Information
1. Infectious Disease Service, Department of Paediatrics, KK Women's and Children's Hospital, Singapore.
- Publication Type:Journal Article
- MeSH:
Child;
Humans;
Female;
Male;
COVID-19/epidemiology*;
Mucocutaneous Lymph Node Syndrome;
Immunoglobulins, Intravenous/therapeutic use*;
Aftercare;
Singapore/epidemiology*;
Patient Discharge
- From:Annals of the Academy of Medicine, Singapore
2022;51(11):669-676
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTION:Multisystem inflammatory syndrome in children (MIS-C) is a rare inflammatory syndrome with multisystem involvement affecting children exposed to COVID-19. This condition is rarely reported in East Asia and was not detected in Singapore until 2021. We present 12 cases of MIS-C diagnosed in KK Women's and Children's Hospital (KKH) from October 2021 to December 2021.
METHOD:We conducted an observational study on cases fulfilling the Singapore Ministry of Health criteria for MIS-C from January 2020 to December 2021 in KKH. Medical records were reviewed to obtain information on clinical presentation, disease course, treatment received and outcomes.
RESULTS:In the 12 cases detected, the median age was 7.50 years (interquartile range 4.00-9.25); 8 were male. All patients had mucocutaneous symptoms similar to Kawasaki disease. Other commonly involved systems were: haematological (coagulopathy 100%, lymphopaenia 91.70% and thrombocytopaenia 75.00%), gastrointestinal (75.00%) and cardiovascular (83.30%). Six patients (50.00%) had shock and were admitted to the intensive care unit. The majority of patients received treatment within 2 days of hospitalisation with intravenous immunoglobulin (IVIg) and steroids. All survived; the majority had normal echocardiograms and no long-term organ sequelae at 6 months post-discharge.
CONCLUSION:MIS-C emerged in Singapore as the incidence of COVID-19 in the community increased in 2021. The clinical presentation of our patients is similar to earlier reports, with some significant differences from Kawasaki disease. Multidisciplinary management, timely diagnosis, and early initiation of treatment with IVIg and steroids likely contributed to comparatively good outcomes. Our cases highlight the need for continued awareness of MIS-C among physicians, and surveillance of its incidence, short- and long-term outcomes.
